UCB and Novartis entered into a license agreement for cardiovascular and diabetes products in Germany. UCB has extended commercial rights for the German market to the cardiovascular drug Provas (valsartan) beyond 2011 and has licensed in commercial rights for two line extensions: Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT). In addition, UCB will co-commercialize the two new oral anti-diabetics Jalra and Icandra (vildagliptin and vildagliptin + metformin).
"With this agreement we are building on our strengths in Germany, our excellent position in the Internal Medicine segment," said Willy Cnops, vice president UCB and managing director Germany. "We are extending our cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options to date in line with UCB's ambitions to offer the best medicines to our patients."
Sign up today for Contracting & Outsourcing 2009!